Pemetrexed in the second line chemotherapy in non-small cell lung cancer. A multicentre prospective analysis of data from clinical practise
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00052778" target="_blank" >RIV/00216224:14110/11:00052778 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Pemetrexed in the second line chemotherapy in non-small cell lung cancer. A multicentre prospective analysis of data from clinical practise
Original language description
Non small cell lung cancer (NSCLC) is one of the most aggressive tumours with unsatisfactory prognosis and extremely high mortality. Pemetrexed became one of the standard chemotherapeutic options in advanced NSCLC. It is recommended both in the 1st lineand in the 2nd line.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů